Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immunomodulation of Tlr2 and Tlr4 by G2013 (Α-L-Guluronic Acid) in Cvid Patients Publisher



Sharifi L1 ; Aghamohammadi A1, 2 ; Mohsenzadegan M3 ; Rezaei N1 ; Zavareh FT1 ; Moshiri M4 ; Bokaie S5 ; Barati A6 ; Sayedi SJ7 ; Azizi G8 ; Mirshafiey A1, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Primary Immunodeficiency Diseases Network (PIDNet), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Microbiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
  6. 6. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Pediatrics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  8. 8. Department of Laboratory Medicine, Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran

Source: International Journal of Pediatrics Published:2017


Abstract

Background: Common variable immunodeficiency (CVID) is a primary immune disorder associated with hypogammaglobulinemia, recurrent infections and autoimmune diseases. CVID patients are frequently in contact with infectious pathogens leading to the activation of innate immunity through Toll-like receptors (TLR) affecting adaptive immunity. The aim of the present study was to test the immunomedulatory effect of small molecule G2013, a novel designed non-steroidal anti-inflammatory agent in CVID. Materials and Methods: After blood sampling from 16 CVID patients and 16 age- and sex-matched healthy controls, peripheral blood mononuclear cells (PBMCs) were isolated and treated with/without lipopolysaccharide (LPS), lipopolyteichoic acid (LTA), and G2013. Assessing the immunomodulatory effect of G2013, flowcytometry was done for quantify the protein expression of TLR2 and TLR4. Gene expressions of signaling molecules involved in the TLR2 and TLR4 pathways were assessed by real-time PCR. ELISA performed assessing the production of IL-1β and IL-6. Results: G2013 significantly decreased the intensity of TLR2 expression in CVID PBMCs (p=0.001) also G2013 decreased significantly the NF-κB gene expression in PBMCs of CVID patients (p=0.006). Conclusion: These results indicated that G2013 had immunomodulatory effect at least in part via TLR2 and NF-κB expression. G2013 by decreasing MFI of TLR2 expression and NFκB gene expression provide the possibility of designing new drugs for preventing or controlling autoimmunity in CVID patients.
Related Docs
View other Related Docs
1. A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency, Endocrine# Metabolic and Immune Disorders - Drug Targets (2017)
2. Immunomodulatory Effect of G2013 (Α-L-Guluronic Acid) on the Tlr2 and Tlr4 in Human Mononuclear Cells, Current Drug Discovery Technologies (2018)
3. The Profile of Toll-Like Receptor 2 (Tlr2), Tlr4 and Their Cytosolic Downstream Signaling Pathway in Common Variable Immunodeficiency (Cvid) Patients, Iranian Journal of Allergy# Asthma and Immunology (2018)
4. Evaluation of the Tlr Negative Regulatory Network in Cvid Patients, Genes and Immunity (2019)
5. The Role of Toll-Like Receptors in B-Cell Development and Immunopathogenesis of Common Variable Immunodeficiency, Expert Review of Clinical Immunology (2016)
6. Interleukin-1Β and Interleukin-6 in Common Variable Immunodeficiency and Their Association With Subtypes of B Cells and Response to the Pneumovax-23 Vaccine, European Cytokine Network (2019)
7. Toll-Like Receptors Pathway in Common Variable Immune Deficiency (Cvid) and X-Linked Agammaglobulinemia (Xla), European Cytokine Network (2018)
8. Common Variable Immunodeficiency: Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, Classification, and Management, Journal of Investigational Allergology and Clinical Immunology (2020)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (15)
Laleh Sharifi (10)
Other Related Docs
9. Antagonistic Property of G2013 (Α-L-Guluronic Acid) on Gene Expression of Myd88, Tollip, and Nf-Κb in Hek293 Tlr2 and Hek293 Tlr4, Endocrine# Metabolic and Immune Disorders - Drug Targets (2019)
10. Impaired Akt Phosphorylation in B-Cells of Patients With Common Variable Immunodeficiency, Clinical Immunology (2017)
11. The Immunomodulatory Role of G2013 (Α-L-Guluronic Acid) on the Expression of Tlr2 and Tlr4 in Ht29 Cell Line, Current Drug Discovery Technologies (2019)
12. The Inhibitory Role of M2000 (Β-D-Mannuronic Acid) on Expression of Toll-Like Receptor 2 and 4 in Ht29 Cell Line, Recent Patents on Inflammation and Allergy Drug Discovery (2019)
13. The Safety and Efficacy of Guluronic Acid (G2013) in Ankylosing Spondylitis: A Randomized Controlled Parallel Clinical Trial, Pharmacological Reports (2019)
14. Primary Immunodeficiencies and Cancers, Cancer Immunology: A Translational Medicine Context (2015)
15. Pivotal Cytokines and Their Transcription Factors Are the Targets of Guluronic Acid (G2013) for Inhibiting the Immunopathogenesis Process of Multiple Sclerosis, Drug Development Research (2020)
16. The Effects of Guluronic Acid (G2013), a New Emerging Treatment, on Inflammatory Factors in Nonalcoholic Steatohepatitis Patients Under in Vitro Conditions, Immunopharmacology and Immunotoxicology (2021)
17. The Application of G2013 (Α-L-Guluronic Acid) As an Anti-Inflammatory Drug Candidate in Treatment of Disease, Journal of Isfahan Medical School (2021)
18. Evaluation of the Acute and 28-Day Sub-Acute Intravenous Toxicity of Α-L-Guluronic Acid (Alg; G2013) in Mice, Drug and Chemical Toxicology (2022)
19. T-Cell Abnormalities in Common Variable Immunodeficiency, Journal of Investigational Allergology and Clinical Immunology (2016)
20. Evaluation of Known Defective Signaling-Associated Molecules in Patients Who Primarily Diagnosed As Common Variable Immunodeficiency, International Reviews of Immunology (2016)
21. Preclinical and Pharmacotoxicology Evaluation of Α-L-Guluronic Acid (G2013) As a Non-Steroidal Anti-Inflammatory Drug With Immunomodulatory Property, Immunopharmacology and Immunotoxicology (2017)
22. Effects of Guluronic Acid (G2013) on Ship1, Socs1 Induction and Related Molecules in Tlr4 Signaling Pathway, International Immunopharmacology (2018)
23. Evaluation of Infectious and Non-Infectious Complications in Patients With Primary Immunodeficiency, Central European Journal of Immunology (2017)
24. Role of Rare Immune Cells in Common Variable Immunodeficiency, Pediatric Allergy and Immunology (2022)
25. Epidemiology and Pathophysiology of Malignancy in Common Variable Immunodeficiency?, Allergologia et Immunopathologia (2017)
26. Anti‐Inflammatory and Anti‐Tumor Effects of Α-L-Guluronic Acid (G2013) on Cancer-Related Inflammation in a Murine Breast Cancer Model, Biomedicine and Pharmacotherapy (2018)
27. Immunophenotypic and Functional Analysis of Lymphocyte Subsets in Common Variable Immunodeficiency Patients Without Monogenic Defects, Scandinavian Journal of Immunology (2022)
28. Assessment of Immunological Profile in Ankylosing Spondylitis Patients Following a Clinical Trial With Guluronic Acid (G2013), As a New Nsaid With Immunomodulatory Properties, Immunologic Research (2019)
29. Β-D-Mannuronic Acid (M2000) As a Landmark in Pharmacology, Current Drug Discovery Technologies (2021)
30. Autoimmunity in Common Variable Immunodeficiency: Epidemiology, Pathophysiology and Management, Expert Review of Clinical Immunology (2017)
31. Predictive Markers for Humoral Influenza Vaccine Response in Patients With Common Variable Immunodeficiency, Journal of Allergy and Clinical Immunology (2018)
32. Autoimmune Disorders Associated With Common Variable Immunodeficiency: Prediction, Diagnosis, and Treatment, Expert Review of Clinical Immunology (2022)
33. Role of Apoptosis in Common Variable Immunodeficiency and Selective Immunoglobulin a Deficiency, Molecular Immunology (2016)
34. Evaluation of the Effect of Α-L-Guluronic Acid (G2013) on Cox-1, Cox-2 Activity and Gene Expression for Introducing This Drug As a Novel Nsaid With Immunomodulatory Property, Recent Patents on Inflammation and Allergy Drug Discovery (2018)
35. A Randomized Clinical Trial for the Assessment of the Efficacy and Safety of Guluronic Acid (G2013) in Patients With Rheumatoid Arthritis, Immunopharmacology and Immunotoxicology (2019)
36. Evaluation of the Oral Administration of Α-L-Guluronic Acid on Cox-1 and Cox-2 Gene Expression Profile in Ankylosing Spondylitis Patients, Drug Development Research (2021)
37. The Open, Randomized, Positive Control Clinical Trial of Guluronic Acid (G2013) on Sars-Cov-2 Patients, Current Drug Discovery Technologies (2023)